|
|
此文章由 jhsun3 原创或转贴，不代表本站立场和观点，版权归 oursteps.com.au 和作者 jhsun3 所有！转贴必须注明作者、出处和本声明，并保持内容完整
本帖最后由 jhsun3 于 2018-8-26 15:08 编辑
tongyang 发表于 2018-8-24 15:45 
MYX 今天怎么了？ 最高到1.425
虽然全能和去年比有点下降，但cash earning 已经恢复normal..而且下半年有一堆products in the pipeline...USB 已经upgrade MYX到1.26,从前1.05...
Hotcopper里在65c时就一直有人在讨论，关注它的每一个消息
https://hotcopper.com.au/asx/myx/
Mayne Pharma Group Ltd (ASX:MYX) shares soar 19% higher on results announcement
By
Lauren Surplice
-
August 24, 2018
Share
The Mayne Pharma Group Ltd (ASX:MYX) share price has soared 19.05% higher to $1.25 early on Friday, on the release of its full-year results.
Revenue fell 7% from the previous corresponding period to $530.3 million, however, second half revenue was up 18% on first-half revenue.
Similarly, second half adjusted EBITDA rose 35% over first-half to $94.8 million, with full-year EBITDA of $165.3 million, down 20% on the year prior.
Mayne Pharma’s CEO, Mr Scott Richards said, “Following a challenging first half, the Company’s performance was substantially stronger in the second half with revenue up 18%, adjusted EBITDA up 35%, adjusted NPAT up 171% and operating cash flow up 53%.”
The company said the second half growth was driven primarily by the rebound in its generic products, with its generic portfolio performing strongly in the second half driven by six new product launches.
Acquisition of generic Efudex
Mayne Pharma announced last month that it had completed the acquisition of generic Efudex (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. for US$20 million. The transaction comprises of US$16 million in cash and US$4 million in Mayne Pharma equity, plus contingent payments of up to US$10 million.
Mayne Pharma will fund the acquisition from cash and undrawn debt and said the acquisition is expected to be immediately EPS accretive with modest incremental EBITDA in FY19.
Outlook
The Company said it will continue to drive organic growth and pursue shareholder value accretive business development opportunities, such as the recently completed the acquisition of generic Efudex while improving profitability and cash flow through an efficient operating model.
Since the beginning of 2018, the Mayne Pharma Group Ltd share price has climbed 66.91% higher, compared to a gain of 3.09% for the S&P/ASX 200 Index.
|
评分
-
查看全部评分
|
澳洲中部匆忙游记(10月13日更新了第六天的内容) (2005-9-20) susan 
Angela的童言童语（四）----21个月 (2009-4-21) Rainyichen 
楼主:sparkz
发表于 2018-7-28 21:15
发表于 2018-8-24 18:53
